The Growth Inhibitory Activity of the Cimicifuga racemosa Extract Ze 450 is Mediated through Estrogen and Progesterone Receptors-Independent Pathways

Abstract

Despite the wide use of Cimicifuga racemosa (CR) extract to treat symptoms associated with menopause and other gynecological disorders, very little is known about its mechanism of action. Therefore, we studied in this report the antiestrogenic and antiproliferative effect of a new CR ethanolic extract, Ze 450, in a MCF-7 cell clone that does not proliferate in response to 17β-estradiol (E₂). Using this cell line, we have found that the extract inhibited cell proliferation and showed antiestrogenic activity using an ERE-luciferase reporter assay. The growth inhibitory activity was different from the antiestrogenic activity since the CR extract also inhibited the growth of the ER-negative human breast cancer cell line T-47D. Also, we evaluated the effects of this CR extract on the transcriptional regulation of genes involved in cell cycle progression in the ER-negative cell lines 293T and T-47D and we found that this extract markedly inhibited the luciferase activity driven by the cyclin D1 promoter and increased the transcriptional activity of the p21 gene promoter. Finally, we observed that our CR extract bound to the progesterone receptor B1 but did not show progestin-like activity in the T-47D cell line. These findings provide new mechanistic insights into the antiproliferative activities of CR in ER-positive and ER-negative tumour cell lines and highlight their potential in the management of climacteric disorders in women with a history of breast cancer.

Cimicifuga racemosa - Ranunculaceae - Ze 450 - breast cancer - estrogen receptor - cyclin D1

References

• 1 Mendelson C R, Simpson E R. Regulation of estrogen biosynthesis by human adipose cells in vitro .  Mol Cell Endocrinol. 1987;  52 169-76
• 2 Muti P. The role of endogenous hormones in the etiology and prevention of breast cancer: the epidemiological evidence.  Ann NY Acad Sci. 2004;  1028 273-82
• 3 Missmer S A, Eliassen A H, Barbieri R L, Hankinson S E. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.  J Natl Cancer Inst. 2004;  96 1856-65
• 4 Gold B, Kalush F, Bergeron J, Scott K, Mitra N, Wilson K. et al . Estrogen receptor genotypes and haplotypes associated with breast cancer risk.  Cancer Res. 2004;  64 8891-900
• 5 Million Women Study C ollaborators. Breast cancer and hormone-replacement therapy in the Million Women Study.  Lancet. 2003;  362 419-27
• 6 Kass-Annese B. Alternative therapies for menopause.  Clin Obstet Gynecol. 2000;  43 162-83
• 7 Borrelli F, Ernst E. Cimicifuga racemosa: a systematic review of its clinical efficacy.  Eur J Clin Pharmacol. 2002;  58 235-41
• 8 Borrelli F, Izzo A A, Ernst E. Pharmacological effects of Cimicifuga racemosa .  Life Sci. 2003;  73 1215-29
• 9 Freudenstein J, Dasenbrock C, Nisslein T. Lack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic Cimicifuga racemosa extract.  Cancer Res. 2002;  62 3448-52
• 10 Zierau O, Bodinet C, Kolba S, Wulf M, Vollmer G. Antiestrogenic activities of Cimicifuga racemosa extracts.  J Steroid Biochem Mol Biol. 2002;  80 125-30
• 11 Einbond L S, Shimizu M, Xiao D, Nuntanakorn P, Lim J T, Suzui M. et al . Inhibitory activity of extracts and purified components of black cohosh on human breast cancer cells.  Breast Cancer Res Treat. 2004;  83 221-31
• 12 Hostanska K, Nisslein T, Freudenstein J, Reichling J, Saller R. Cimicifuga racemosa extract inhibits proliferation of estrogen receptor-positive and negative human breast carcinoma cell lines by induction of apoptosis.  Breast Cancer Res Treat. 2004;  84 151-60
• 13 Joe A K, Arber N, Bose S, Heitjan D, Zhang Y, Weinstein I B. et al . Cyclin D1 overexpression is more prevalent in non-Caucasian breast cancer.  Anticancer Res. 2001;  21 3535-9
• 14 Stromeier S, Petereit F, Nahrstedt A. Phenolic esters from the rhizomes of Cimicifuga racemosa do not cause proliferation effects in MCF-7 cells.  Planta Med. 2005;  71 495-500
• 15 Liu J, Burdette J E, Xu H, Gu C, van Breemen R B, Bhat K PL. et al . Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms.  J Agric Food Chem. 2001;  49 2472-9
• 16 Hamelers I H, van Schaik R F, Sussenbach J S, Steenbergh P H. 17beta-Estradiol responsiveness of MCF-7 laboratory strains is dependent on an autocrine signal activating the IGF type I receptor.  Cancer Cell Int. 2003;  3 10
• 17 Barak Y, Gottlieb E, Juven-Gershon T, Oren M. Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential.  Genes Dev. 1994;  8 1739-49
• 18 El-Deiry W S, Tokino T, Velculescu V E, Levy D B, Parsons R, Trent J M. et al . WAF1, a potential mediator of p53 tumor suppression.  Cell. 1993;  75 817-25
• 19 Watanabe G, Lee R J, Albanese C, Rainey W E, Batlle D, Pestell R G. Angiotensin II activation of cyclin D1-dependent kinase activity.  J Biol Chem. 1996;  271 22 570-7
• 20 Kobayashi Y, Kitamoto T, Masuhiro Y, Watanabe M, Kase T, Metzger D. et al . p300 mediates functional synergism between AF-1 and AF-2 of estrogen receptor alpha and beta by interacting directly with the N-terminal A/B domains.  J Biol Chem. 2000;  275 15 645-51
• 21 Zava D T, Dollbaum C M, Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices.  Proc Soc Exp Biol Med. 1998;  217 369-78
• 22 Cadepond F, Ulmann A, Baulieu E E. RU486 (mifepristone): mechanisms of action and clinical uses.  Annu Rev Med. 1997;  48 129-56
• 23 Iwasaki K, Underwood B, Herman M, Dinda S, Kodali S, Kloosterboer H J. et al . Effects of antiprogestins on the rate of proliferation of breast cancer cells.  Mol Cell Biochem. 1999;  198 141-9

1 MGH and MAC contributed equally to this work